A detailed history of Two Sigma Investments, LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Two Sigma Investments, LP holds 482,136 shares of VRDN stock, worth $10.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
482,136
Previous 419,820 14.84%
Holding current value
$10.4 Million
Previous $5.46 Million 100.84%
% of portfolio
0.03%
Previous 0.01%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$12.16 - $23.33 $757,762 - $1.45 Million
62,316 Added 14.84%
482,136 $11 Million
Q2 2024

Aug 14, 2024

BUY
$11.6 - $17.26 $2.24 Million - $3.33 Million
192,966 Added 85.06%
419,820 $5.46 Million
Q1 2024

May 15, 2024

BUY
$17.09 - $23.82 $3.88 Million - $5.4 Million
226,854 New
226,854 $3.97 Million
Q2 2023

Aug 14, 2023

BUY
$22.57 - $29.67 $474,376 - $623,604
21,018 New
21,018 $500,000

Others Institutions Holding VRDN

About Viridian Therapeutics, Inc.\DE


  • Ticker VRDN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,888,900
  • Market Cap $859M
  • Description
  • Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...
More about VRDN
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.